Non-dystrophic myopathy

Non-dystrophic myopathy (Orphanet code 206656) is a broad grouping of inherited muscle disorders characterized by skeletal muscle dysfunction that does not involve the progressive muscle fiber degeneration and replacement by fibrotic or fatty tissue typically seen in muscular dystrophies. Instead, these conditions affect muscle function through other mechanisms, such as structural abnormalities of muscle fibers, metabolic defects, or ion channel dysfunction. The primary body system affected is the skeletal muscular system, though cardiac and respiratory involvement may occur depending on the specific subtype. Key clinical features can include muscle weakness (which may be proximal, distal, or generalized), muscle stiffness, exercise intolerance, hypotonia, and in some cases respiratory insufficiency. The severity and distribution of symptoms vary widely depending on the underlying genetic cause. Some forms present in the neonatal or infantile period with severe hypotonia and feeding difficulties, while others may not become apparent until childhood or adulthood with milder weakness or episodic symptoms. Treatment for non-dystrophic myopathies is largely supportive and symptom-based. Management may include physical therapy and rehabilitation to maintain mobility and function, respiratory support when needed, and careful monitoring of cardiac function in subtypes with potential cardiac involvement. Specific pharmacological treatments exist for certain subtypes, such as medications for non-dystrophic myotonias (e.g., mexiletine for myotonic symptoms). Genetic counseling is recommended for affected individuals and their families. Research into targeted therapies, including gene therapy approaches, is ongoing for several subtypes within this category.

Common questions about Non-dystrophic myopathy